Pfizer (PFE.US) anti-infection blockbuster new innovative drug new dosage form approved for market in China further improving the treatment system for invasive fungal infections in children.

According to the Wise Finance APP, on May 27th, Pfizer (PFE.US) announced that its anti-infection blockbuster innovative drug Xue Xin Bo 200mg injection (generic name: injection of isavuconazole sulfate) and 100mg oral capsule (generic name: isavuconazole sulfate capsule) have obtained approval for pediatric indications from the National Medical Products Administration (NMPA) of China, further improving the treatment coverage from children to adults of all ages.